Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it

Page 4 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Dapagliflozin in Acute Heart FailureCompletedNCT04298229Phase 3Results posted
• A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With DiabetesCompletedNCT04288778Phase 4Results posted
• A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart FailureCompletedNCT04252287Phase 3Results posted
• Dapagliflozin at Discharge on Hospital Heart Failure ReadmissionCompletedNCT04249778Phase 4Results posted
• A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take InsulinCompletedNCT04233801Phase 3Results posted
• Ertugliflozin for Functional Mitral RegurgitationCompletedNCT04231331Phase 3Results posted
• Ertugliflozin: Cardioprotective Effects on Epicardial FatCompletedNCT04167761Early Phase 1Results posted
• A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart FailureCompletedNCT04157751Phase 3Results posted
• Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart FailureTerminatedNCT04071626Phase 4Results posted
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.TerminatedNCT04065841Phase 2Results posted
• Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)CompletedNCT04029480Phase 3Results posted
• Effectiveness of Dapagliflozin for Weight LossCompletedNCT03968224Phase 2/3Results posted
• DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection FractionCompletedNCT03877237Phase 3Results posted
• DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection FractionCompletedNCT03877224Phase 3Results posted
• Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone ProductionCompletedNCT03852901Phase 1Results posted
• Dapagliflozin In Alzheimer's DiseaseCompletedNCT03801642Phase 1/2Results posted
• Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2CompletedNCT03782259Phase 4Results posted
• Effect of Ertugliflozin on Cardiac Function in DiabetesCompletedNCT03717194Phase 3Results posted
• Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes MellitusTerminatedNCT03660683Phase 4Results posted
• This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate PillsCompletedNCT03629054Phase 1Results posted
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.CompletedNCT03619213Phase 3Results posted
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)CompletedNCT03594110Phase 3Results posted
• Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic ImpairmentCompletedNCT03557658Phase 1Results posted
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)TerminatedNCT03521934Phase 3Results posted
• An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential HypertensionCompletedNCT03514641Phase 2/3Results posted
• Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).CompletedNCT03485222Phase 4Results posted
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure SymptomsCompletedNCT03448419Phase 3Results posted
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.CompletedNCT03448406Phase 3Results posted
• Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic NephropathyCompletedNCT03436693Phase 3Results posted
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TMCompletedNCT03429543Phase 3Results posted
• ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart FailureCompletedNCT03416270Phase 2Results posted
• A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes PatientsCompletedNCT03387683Phase 4Results posted
• Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTerminatedNCT03386344Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompletedNCT03351478Phase 3Results posted
• Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.CompletedNCT03338855Phase 4Results posted
• Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCompletedNCT03332771Phase 3Results posted
• A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take EmpagliflozinCompletedNCT03332212Phase 3Results posted
• Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in GlucosuriaCompletedNCT03331289Phase 4Results posted
• A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With ObesityCompletedNCT03320941Phase 2Results posted
• A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UACompletedNCT03316131Phase 2Results posted
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskTerminatedNCT03315143Phase 3Results posted
• Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureTerminatedNCT03292653Phase 2Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCompletedNCT03285594Phase 3Results posted
• An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on MetforminCompletedNCT03267576Phase 4Results posted
• This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the BloodCompletedNCT03259490Phase 1Results posted
• Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCompletedNCT03242252Phase 3Results posted
• A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCompletedNCT03242018Phase 3Results posted
• SGLT2 Inhibition in Combination With Diuretics in Heart FailureCompletedNCT03226457Phase 4Results posted
• Effect of LIK066 on Reduction of Fatty Content in Livers of Obese PatientsCompletedNCT03205150Phase 2Results posted
• Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart FailureCompletedNCT03200860Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldCompletedNCT03199053Phase 3Results posted
• Bexagliflozin Drug/Drug Interaction Study With DigoxinCompletedNCT03197324Phase 1Results posted
• Empagliflozin and Hepatic Glucose MetabolismCompletedNCT03193684Phase 4Results posted
• Effects of Dapagliflozin in Non-diabetic Patients With ProteinuriaCompletedNCT03190694Phase 2Results posted
• Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?CompletedNCT03180489Phase 2Results posted
• A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes MellitusCompletedNCT03170518Phase 3Results posted
• Bexagliflozin Drug/Drug Interaction Study With Exenatide InjectionCompletedNCT03167411Phase 1Results posted
• Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary SyndromeCompletedNCT03152591Phase 2Results posted
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureTerminatedNCT03152552Phase 2Results posted
• The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.TerminatedNCT03152084Phase 4Results posted
• Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.CompletedNCT03131479Phase 2Results posted
• Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsCompletedNCT03115112Phase 3Results posted
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight AdultsCompletedNCT03100058Phase 2Results posted
• Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial InfarctionCompletedNCT03087773Phase 3Results posted
• Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)CompletedNCT03074630Phase 4Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCompletedNCT03066830Phase 3Results posted
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)CompletedNCT03057977Phase 3Results posted
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)CompletedNCT03057951Phase 3Results posted
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney DiseaseCompletedNCT03036150Phase 3Results posted
• Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart FailureCompletedNCT03036124Phase 3Results posted
• Dapagliflozin in PRESERVED Ejection Fraction Heart FailureCompletedNCT03030235Phase 4Results posted
• Empagliflozin Impact on Hemodynamics in Patients With Heart FailureCompletedNCT03030222Phase 4Results posted
• Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and PrehypertensionCompletedNCT03006471Phase 4Results posted
• Paradoxical Stimulation of Hepatic Glucose Production With DapagliflozinCompletedNCT02984644Phase 3Results posted
• Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism SubjectsCompletedNCT02981966Phase 4Results posted
• Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DMCompletedNCT02981069Phase 4Results posted
• Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)CompletedNCT02973477Phase 4Results posted
• Role of Canagliflozin on CD34+ Cells in Patients With Type 2 DiabetesCompletedNCT02964585Phase 4Results posted
• An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesCompletedNCT02962492Not applicableResults posted
• Interaction of Bexagliflozin With Metformin, Glimepiride and SitagliptinCompletedNCT02956044Phase 1Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCompletedNCT02926950Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCompletedNCT02926937Phase 3Results posted
• Treatment of Diabetes in Patients With Systolic Heart FailureCompletedNCT02920918Phase 4Results posted
• CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 DiabetesTerminatedNCT02912455Phase 4Results posted
• Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With HyperfiltrationCompletedNCT02911792Phase 4Results posted
• Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?CompletedNCT02846233Not applicableResults posted
• Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal ImpairmentCompletedNCT02836873Phase 3Results posted
• Visceral Adiposity and Diabetes: Translating Form to Function Using ImagingCompletedNCT02833415Phase 4Results posted
• Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy SubjectsCompletedNCT02820298Phase 1Results posted
• Empa/Lina FDC Food Effect Study (Japan)CompletedNCT02815644Phase 1Results posted
• Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 DiabetesCompletedNCT02796170Phase 4Results posted
• Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 DiabetesCompletedNCT02777073Not applicableResults posted
• Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsCompletedNCT02769481Phase 3Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female SubjectsCompletedNCT02758171Phase 1Results posted
• Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 YearsCompletedNCT02725593Phase 3Results posted
• An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed ConditionsCompletedNCT02722239Phase 1Results posted
• Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 DiabetesCompletedNCT02715258Phase 3Results posted
• Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With PrediabetesCompletedNCT02700334Phase 4Results posted
• Renoprotective Effects of Dapagliflozin in Type 2 DiabetesCompletedNCT02682563Phase 4Results posted
• A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 DiabetesCompletedNCT02681094Phase 3Results posted

← Sodium-Glucose Transporter 2 Inhibitors overview